CLEARWATER, Fla. - Apyx Medical Corporation (NASDAQ:APYX) announced the publication of clinical study results in Aesthetic Surgery Journal Open Forum examining a combination treatment approach for cellulite and skin laxity.
The prospective study evaluated Avéli for targeted subcision followed by Renuvion to reduce skin laxity. 22 patients received a single session. At 180 days, up to 81.8% showed improvement in cellulite appearance.
Regis Cain, Senior Director of Marketing at Apyx Medical, said, "As the patient profile evolves, a more comprehensive approach to cellulite and skin laxity is needed."
Barry E. DiBernardo, MD, lead investigator, stated, "Cellulite and skin laxity are complex concerns that often require a multi-modality approach."
Apyx Medical markets Renuvion, the AYON Body Contouring System, and J-Plasma. The company's shares have returned 156% over the past year but currently trade at $3.79.
